RecruitingPhase 2NCT07281456
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Bethesda, MD
Phase 2 Rheumatoid Arthritis clinical trials
14 recruiting Phase 2 rheumatoid arthritis studies in the US. What trial phases mean
Other phases
RecruitingPhase 2NCT07137598
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Sponsor: Hoffmann-La Roche
Avondale, AZ · Peoria, AZ · La Jolla, CA · +15 more sites
RecruitingPhase 2NCT07620392
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
Sponsor: Hoffmann-La Roche
Tamarac, FL · Lake Charles, LA · Houston, TX · +2 more sites
RecruitingPhase 2NCT07737743
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Sponsor: Novartis Pharmaceuticals
Clearwater, FL · Tampa, FL · Chicago, IL · +6 more sites
RecruitingPhase 2NCT07276581
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Sponsor: AstraZeneca
Glendale, AZ · Prescott Valley, AZ · Tucson, AZ · +26 more sites
RecruitingPhase 2NCT06972446
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Sponsor: AbbVie
Peoria, AZ · Jonesboro, AR · Beverly Hills, CA · +46 more sites
RecruitingPhase 2NCT06570798
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Sponsor: Amgen
Scottsdale, AZ · Aurora, CO · Hialeah, FL · +15 more sites
RecruitingPhase 2NCT06991114
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Sponsor: Artiva Biotherapeutics, Inc.
Tuscaloosa, AL · Phoenix, AZ · Tucson, AZ · +28 more sites
RecruitingPhase 2NCT07409103
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Sponsor: Elevara Medicines Limited
Gilbert, AZ · Glendale, AZ · Tucson, AZ · +19 more sites
RecruitingPhase 2NCT07138898
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Sponsor: NYU Langone Health
New York, NY
RecruitingPhase 2NCT01962415
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Sponsor: Paul Szabolcs
Pittsburgh, PA
RecruitingPhase 2NCT06072768
Dynamic Treatment Regiments for Glucocorticoid Tapering
Sponsor: VA Office of Research and Development
Ann Arbor, MI
RecruitingPhase 2NCT06671054
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Sponsor: SynAct Pharma Aps
Cutler Bay, FL · Miami, FL · Duncansville, PA
Not yet recruitingPhase 2NCT07534332
Disulfiram in Rheumatoid Arthritis
Sponsor: University of Oklahoma
Oklahoma City, OK
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.